Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program ( EAP )
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70122 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Akimichi Morita und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Interleukins, Dermatologic Agents. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Generalized pustular psoriasis (GPP) is a heterogeneous, systemic neutrophilic inflammatory disease, characterized by chronic symptoms and recurrent flares, which can be potentially life‐threatening. Spesolimab, an interleukin‐36 receptor antagonist, has been approved to treat GPP flares in many countries including Japan. An expanded access program (EAP) in Japan provided early access to spesolimab for patients aged 18–75 years unable to participate in a clinical trial with no other treatment options. Patients received a single dose of 900 mg intravenous spesolimab for flare treatment, with an optional second dose after 1 week if symptoms persisted. Safety was monitored for 16 weeks post‐treatment. Eleven patients (54.5% female; 51 years mean age; 26.7 kg/m 2 mean body mass index) received 23 doses of intravenous spesolimab. Nine patients (81.8%) were diagnosed with GPP for > 5 years. Ten patients (90.9%) had ≥ 1 baseline medical condition. All patients used ≥ 1 concomitant medication prior to or during the spesolimab treatment period, most commonly immunosuppressants and non‐steroidal anti‐inflammatory agents. Seven patients (63.6%) experienced treatment‐emergent adverse events, all of mild or moderate intensity, including skin and subcutaneous tissue disorders, general disorders and administration site conditions. No adverse event led to treatment discontinuation or death. A potential hypersensitivity event (face edema) resolved without intervention and was not considered treatment related. Spesolimab was well tolerated in a heterogeneous patient population with GPP, including those with comorbidities and concomitant medication use. The safety profile of spesolimab aligned with the EFFISAYIL 1 clinical trial results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
- Saitama Medical University Hospital, Saitama, Japan.
- Jichi Medical University Hospital, Tochigi, Japan.
- Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
- Fukuoka University Hospital, Fukuoka, Japan.
ORCID-Profile: Akimichi Morita, Yayoi Tada, Mayumi Komine, Shinichi Imafuku, Toshiya Takahashi
Förderung
- Boehringer Ingelheim
Zitieren
APA
Morita, A., Tada, Y., Tsunemi, Y., Komine, M., Kanekura, T., Imafuku, S., Takahashi, T., Ding, X., Pillai, N., Saitoh, M., Simoes, R. S., Pöntynen, N., & Yamanaka, K. (2026). Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program ( EAP ). The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70122
Vancouver
Morita A, Tada Y, Tsunemi Y, Komine M, Kanekura T, Imafuku S, et al. Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program ( EAP ). The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70122
BibTeX
@article{Morita2026,
author = {Morita, Akimichi and Tada, Yayoi and Tsunemi, Yuichiro and Komine, Mayumi and Kanekura, Takuro and Imafuku, Shinichi and Takahashi, Toshiya and Ding, Xuemei and Pillai, Nichiren and Saitoh, Morihisa and Simoes, Rafael Sani and Pöntynen, Nora and Yamanaka, Keiichi},
title = {Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program ( EAP )},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70122}
}
EUVIMED